Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the target of a significant decline in short interest in July. As of July 31st, there was short interest totaling 87,627 shares, a decline of 36.2% from the July 15th total of 137,249 shares. Based on an average daily trading volume, of 19,324 shares, the days-to-cover ratio is currently 4.5 days. Currently, 5.8% of the company’s shares are sold short.

Aptevo Therapeutics Stock Down 5.9%

Shares of APVO opened at $2.73 on Thursday. Aptevo Therapeutics has a fifty-two week low of $2.60 and a fifty-two week high of $48.78. The firm’s 50 day moving average price is $4.25 and its 200 day moving average price is $4.96. The company has a market cap of $4.91 million, a P/E ratio of -0.01 and a beta of 1.65.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($5.31) EPS for the quarter, topping the consensus estimate of ($6.02) by $0.71. Research analysts forecast that Aptevo Therapeutics will post -19.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Aptevo Therapeutics has an average rating of “Hold”.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC bought a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned 1.16% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 8.06% of the stock is owned by hedge funds and other institutional investors.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.